Ironwood Pharmaceuticals Inc
Avatud
SektorTervishoid
4.48 -4.48
Ülevaade
Aktsiahinna muutus
24h
Min
4.37
Max
4.75
Sissetulek | -21M 41M |
|---|---|
Müük | 59M 107M |
P/E Sektori keskmine | 7.065 60.549 |
Aktsiakasum | 0.24 |
Kasumimarginaal | 38.282 |
Töötajad | 100 |
EBITDA | 66M 75M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +7.07% upside |
Turukapital | -35M 721M |
|---|---|
Eelmine avamishind | 8.96 |
Eelmine sulgemishind | 4.48 |
Ironwood Pharmaceuticals Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Ironwood Pharmaceuticals Inc Prognoos
Hinnasiht
By TipRanks
7.07% tõus
12 kuu keskmine prognoos
Keskmine 5 USD 7.07%
Kõrge 5 USD
Madal 5 USD
Põhineb 2 Wall Streeti analüütiku instrumendi Ironwood Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.